Work

Transforming hypercholesterolemia management: Spotlight on PCSK9 peptide vaccines

Year: 2024

Type: article

Abstract: Proprotein convertase subtilisin/kexin type 9 (PCSK9) is a therapeutic target for dyslipidemia and atherosclerotic cardiovascular disease (ASCVD). Two recent studies published by Fang et al. 1 and Zhang et al. 2 in Cell Reports Medicine and Cell Reports , respectively, show the efficacy of peptide vaccines in eliciting an antibody response against PCSK9 and reducing plasma cholesterol levels. Proprotein convertase subtilisin/kexin type 9 (PCSK9) is a therapeutic target for dyslipidemia and atherosclerotic cardiovascular disease (ASCVD). Two recent studies published by Fang et al. and Zhang et al. in Cell Reports Medicine and Cell Reports , respectively, show the efficacy of peptide vaccines in eliciting an antibody response against PCSK9 and reducing plasma cholesterol levels.

Source: Cell Reports Medicine

DOI: 10.1016/j.xcrm.2024.101726

Authors: Amirhossein Sahebkar, Maciej Banach

Institutions: Mashhad University of Medical Sciences, Saveetha University, Johns Hopkins University, Johns Hopkins Medicine, Medical University of Lodz

Language: English

Topic: Lipoproteins and Cardiovascular Health

Subfield: Surgery

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: gold

Estimated APC paid: $5,460